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Abstract
Pulmonary arterial hypertension (PAH) is increasingly recognized as a systemic disease driven by alteration in the normal func-
tioning of multiple metabolic pathways affecting all of the major carbon substrates, including amino acids. We found that human
pulmonary hypertension patients (WHO Group I, PAH) exhibit systemic and pulmonary-specific alterations in glutamine metab-
olism, with the diseased pulmonary vasculature taking up significantly more glutamine than that of controls. Using cell culture
models and transgenic mice expressing PAH-causing BMPR2 mutations, we found that the pulmonary endothelium in PAH shunts
significantly more glutamine carbon into the tricarboxylic acid (TCA) cycle than wild-type endothelium. Increased glutamine
metabolism through the TCA cycle is required by the endothelium in PAH to survive, to sustain normal energetics, and to
manifest the hyperproliferative phenotype characteristic of disease. The strict requirement for glutamine is driven by loss of
sirtuin-3 (SIRT3) activity through covalent modification by reactive products of lipid peroxidation. Using 2-hydroxybenzylamine, a
scavenger of reactive lipid peroxidation products, we were able to preserve SIRT3 function, to normalize glutamine metabolism,
and to prevent the development of PAH in BMPR2 mutant mice. In PAH, targeting glutamine metabolism and the mechanisms that
underlie glutamine-driven metabolic reprogramming represent a viable novel avenue for the development of potentially disease-
modifying therapeutics that could be rapidly translated to human studies.
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Alterations in the normal metabolic strategies utilized by
various cell types are increasingly recognized as part of
a central pathogenic mechanism in pulmonary arterial hyper-
tension (PAH).1,2 Any given cell type—endothelium, smooth
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muscle, myocardium, skeletal muscle, etc.—exhibits a ‘‘meta-
bolic program’’ under healthy, homeostatic conditions that is
the sum total of the use and fate of all of the available carbon
sources (primarily carbohydrates, fats, and amino acids). The
details of a cell’s metabolic program are often particular for
that cell type. For example, under normal conditions, cardiac
myocytes primarily oxidize fatty acids as an energy source,
whereas endothelial cells preferentially use glucose through
oxidative and non-oxidative pathways.3,4 Any perturbation
that places demands upon a cell to increase energy production,
to increase macromolecule synthesis, or to resist pro-death sti-
muli will place a strain on the cell’s carbon resources and neces-
sarily change the cell’s metabolic program. Conversely,
anything that restricts a cell’s ability to use one or more
carbon substrates can induce a metabolic reprogramming
that will often change one or more fundamental properties of
the cell, such as differentiation state, proliferative rate, or sen-
sitivity to apoptosis. Thus, a cell’s metabolic program is inex-
tricably linked to the role that cell plays in health and disease.
In PAH, it is well recognized that multiple cell types
involved in disease pathogenesis exhibit a metabolic
reprogramming characterized by increased shunting of glu-
cose-derived carbon into non-oxidative, lactate-producing
pathways in spite of the presence of ample oxygen supply to
permit oxidative glucose metabolism.1,2,5–7 This is colloquially
referred to as the ‘‘Warburg effect,’’ first described by Otto
Warburg as a feature of cancer cells. However, the network of
metabolic pathways within a cell is highly interconnected and
it is rare for one pathway to be altered in isolation. Indeed, it
is increasingly recognized that fatty acid metabolism is also
markedly altered in PAH and that the reciprocal relationship
between glucose and fatty acid oxidation (the so-called
‘‘Randle cycle’’) is abnormal in PAH and likely contributes
to pathogenesis in both the heart and in the pulmonary vas-
culature.8–13 The third major cellular carbon source—amino
acids generally, and glutamine specifically—remains relatively
understudied in PAH.14 Though amino acids represent the
third major carbon source used by most cells, amino acid
trafficking has mainly been studied in PAH in the context of
nitric oxide synthesis. Recent discoveries in cancer biology
have placed amino acids generally, and glutamine specifically,
in central roles for biosynthesis, cellular energetics, and redox
homeostasis.15–18 In the present study, we sought to examine
glutamine metabolism in PAH in the specific context of dys-
functional signaling through bone morphogenic protein recep-
tor type 2 (BMPR2). We hypothesized that the pulmonary
endothelium in PAH would exhibit an abnormal increase in
glutamine metabolism as a primary carbon source, in a
manner similar to what has been observed in cancer.
Materials and methods
Reagents
13C5-L-glutamine was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Chetomin was purchased from
Cayman Chemical (Ann Arbor, MI, USA). 2-hydroxyben-
zylamine (2HOBA) was synthesized at Vanderbilt as pre-
viously described.19 Antibodies were purchased as follows:
HIF1a and glutamine synthetase, Novus Biologicals
(Littleton, CO, USA); Sirt3 and a-tubulin, Cell Signaling
Technology (Danvers, MA, USA); acetyl-lysine, EMD
Millipore (Billerica, MA, USA); and Cox4 and histone
H3, Abcam (Cambridge, MA, USA). Recombinant human
SIRT3 was purchased from R&D Systems (Minneapolis,
MN, USA). Sirt-Glo assay kit was purchased from
Promega (Madison, WI, USA) and used according to the
manufacturer’s instructions.
Cell culture
We used previously characterized wild-type (WT) and
BMPR2 mutant (BMPR2R899X) pulmonary microvascular
endothelial cells (PMVECs) isolated from conditionally
immortalized murine lines generated on the ImmortoMouse
background,20 and WT and BMPR2 mutant PMVECs from
a parent immortalized human line stably expressing either a
WT or BMPR2 mutant construct transfected into the parent
line and maintained under selection with G418S. For murine
lines, cells were reverted to a primary endothelial phenotype
by removal of murine interferon-gamma and transition
to 37C (from 33C, which maintains conditional immortal
phenotype through expression of SV40 large T), and
doxycycline (300ng/mL) was added to the media to induce
expression of the transgene (the construct being Rosa26-
rtTA x TetO7-Bmpr2
R899X, the same as that used in Animal
Studies), both for at least 72h prior to experiments.
Human lines stably express WT or mutant BMPR2, and
selection with G418S was discontinued for 24h prior to
experiments.
Metabolic fluxes and stable isotope labeling
Glucose and lactate levels were measured using the YSI 2300
Stat Glucose and Lactate Analyzer (Yellow Springs, OH,
USA). High performance liquid chromatography (HPLC)
was used to quantify amino acid concentrations with norva-
line as an internal standard. Amino acid samples were then
injected onto a Zorbax Eclipse Plus C18 column (Agilent)
using a two-phase chromatography method as previously
described.21 For isotope tracer studies, WT and BMPR2
mutant PMVECs were cultured in media containing
2mM [U-13C5]-glutamine in place of unlabeled glutamine
for 24 h. Analytes were extracted into ice-cold methanol
and separated in 1:1 chloroform:H2O. The aqueous phase
containing the amino and organic acids was then dried
under air at room temperature. The samples were deriva-
tized using MBTSTFAþ 1% TBDMCS (Pierce). A total
of 2 mL of each derivatized sample was then injected onto
30m DB-35ms capillary column in an Agilent 6890N/5975B
GC-MS. Flux rates were calculated using the ETA software
package.22
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Cell proliferation assays
Cells were seeded and grown under specified media condi-
tions as outlined in the ‘‘Results’’ section. Cells were counted
for total and live cells using Trypan blue exclusion, and auto-
mated counts were done using a Countess cell counter
(Life Technologies, Grand Island, NY, USA).
Two-photon autofluorescence measurement
of optical redox ratio
Two-photon images were acquired and analyzed as
described previously.23 Briefly, cells were plated at a consis-
tent density on glass-bottomed dishes and imaged 48 h later.
A two-photon microscope (Bruker) and 40 oil-immersion
objective (1.3NA) were used to acquire NADH and FAD
autofluorescence images for the same fields of view. Images
were imported into MATLAB (Mathworks) and the NADH
intensity was divided by the FAD intensity for each pixel to
calculate a redox ratio image. The redox ratio was averaged
across each image.
Mitochondrial functional studies
To assess mitochondrial respiration in cultured PMVECs,
cells were seeded in growth media in a 96-well plate from
Seahorse Biosciences (Bilerica, MA, USA) at a seeding
density of 50,000 live cells per well. The following day,
cells were washed and placed in Seahorse Assay Media sup-
plemented with specific substrates (1 gm/L glucose, 2mM L-
glutamine). After equilibration, oxygen consumption rates
were measured on a Seahorse XFe96 analyzer using the
Mito Stress Test protocol.
For mitochondrial protein measurements, mitochondria
were isolated from fresh murine liver tissue as previously
described.24
Animal studies
All animal studies were approved by the Vanderbilt
IACUC. Male and female FVB/N mice were aged 10–16
weeks. BMPR2R899X mice were generated and maintained
as previously described.24,25 For 2HOBA studies, 1 gm/L
was administered in the drinking water, with water bottles
protected from light and water changes every 2–3 days.
Echocardiography was performed on anesthetized mice
(isoflurane anesthesia) to determine cardiac output. Right
ventricular systolic pressure (RVSP) was invasively measured
as described, using bromoethanol as the anesthetic.24,25
Human studies
All human studies were approved by the Institutional
Review Boards of Vanderbilt University, the University of
North Carolina at Chapel Hill, and Yale University.
Informed consent was obtained from each patient. For mea-
surements of circulating glutamine levels, blood samples
were obtained by peripheral venipuncture, centrifuged to
separate plasma, and stored at –80C until analysis.
Amino acid profiles were quantified in Vanderbilt’s clinical
chemistry laboratory using a standard CLIA-approved
method. For transpulmonary measurements, samples were
obtained at the time of clinically indicated diagnostic right
heart catheterization as previously described.26,27 Patients
were classified as having pulmonary hypertension (PH)
based upon the results of invasive hemodynamic testing,
with differences between WHO groups determined by clin-
ical history.
Statistical analyses
All statistics were performed using GraphPad Prism 6.0 or
Microsoft Excel unless otherwise specified. For animal
experiments, sample sizes were chosen based upon previous
experiments with approximately 80% of transgenic animals
showing RVSP> 30mmHg. Animals were randomly
assigned to treatment groups by cage. For all measurements,
investigators were blind to treatments and genotype until
data analysis. Data were analyzed using two-tailed t-test
or two-way ANOVA with Tukey’s post-test, as indicated.
Significance was set at a< 0.05 after correction for multiple
comparisons.
Results
Glutamine metabolism is abnormal
in human PAH patients
To test the hypothesis that PAH involves alteration of glu-
tamine metabolism, we quantified fasting serum glutamine
levels in heritable PAH patients with known BMPR2 muta-
tions, in unaffected mutation carriers (individuals with
known BMPR2 mutations but no evidence of PAH), and
in married-in controls from the same households as patients
and carriers. We found that circulating glutamine levels
were significantly elevated in both heritable PAH patients
(451 68 umol/L) and in BMPR2 mutation carriers
(450 50 umol/L) compared to controls (399 82 umol/L,
P< 0.05, Fig. 1a). This was somewhat unexpected, as pre-
vious work has suggested increased cardiac glutamine
uptake is a feature of the aberrant metabolic program in
PAH.14 To better quantify glutamine metabolism within
the pulmonary vasculature, we measured transpulmonary
glutamine gradients in WHO Group I PAH patients,
WHO Group III PH patients, and individuals with normal
pulmonary hemodynamics. Samples were collected from the
main pulmonary artery (PA) and from the pulmonary capil-
lary wedge (PCW) position at the time of diagnostic right
heart catheterization.26 Glutamine concentrations were
quantified in each sample and the difference between the
PCW and the PA samples for each individual was the gra-
dient measurement (negative values indicate net uptake,
positive values indicate net release). WHO Group I PAH
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patients showed substantial glutamine uptake by the pul-
monary vasculature compared to WHO Group III patients
and to controls (Fig. 1b). Taken together, these data indi-
cated that PAH patients with abnormal BMPR2 function
have marked changes in whole body and in pulmonary vas-
cular glutamine metabolism.
BMPR2 mutant endothelium exhibits
abnormal avidity for glutamine carbon
We next sought to determine whether increased glutamine
uptake by pulmonary endothelial cells with dysfunctional
BMPR2 is an intrinsic property of those cells or merely
due to the increased availability of glutamine. To assess
this, we grew WT and BMPR2 mutant PMVECs in culture
and provided glutamine in significant excess (2mM) of
physiologic levels in the culture media. Under conditions
of glutamine excess, BMPR2 mutant PMVEC took up
glutamine at twice the rate of WT cells (Fig. 2a), suggesting
that increased glutamine uptake is intrinsic to PMVEC with
dysfunctional BMPR2 signaling.
Glutamine can be used as a source of carbon input to the
tricarboxylic acid (TCA) cycle, but it is also an important
source of nitrogen in the cell, supplying nitrogen-requiring
processes such as nucleotide synthesis. We hypothesized that
glutamine was being used as a carbon source and that it was
being preferentially shunted to the TCA cycle in BMPR2
mutant PMVEC compared to WT. To test this hypothesis,
WT and BMPR2 mutant PMVEC were cultured for 24 h in
the presence of 2mM [U-13C5]-L-glutamine, a stable isotope
of glutamine in which all five carbon atoms are carbon-13,
which is easily detectable by mass spectrometry (see sche-
matic Fig. 2b). The other major cellular carbon sources
(glucose, fatty acids) were left unlabeled and the serum
used had been dialyzed to remove free amino acids.
Compared to WT, BMPR2 mutant PMVECs showed
excess incorporation of glutamine-derived carbon in multi-
ple intermediates of the TCA cycle (Fig. 2c). Furthermore,
when specific TCA intermediates (e.g. malate) were broken
down by tandem mass spectrometry to determine how many
glutamine-derived carbon atoms had been incorporated
(0, 1, 2, 3, or 4 for malate), we found that the majority of
malate present (40%) contained four atoms of 13C, indicat-
ing that the majority of the carbon in the TCA cycle was
coming from glutamine, as this was the sole source of 13C
available (Fig. 2d). By contrast, in WT PMVECs, the major-
ity of the malate present (>55%) contained no atoms of 13C,
indicating that in WT cells, the majority of the carbon in the
TCA cycle was not coming from glutamine but rather from
the unlabeled glucose and fatty acids present.
Glutamine is a required carbon source
for BMPR2 mutant PMVECs
We next wanted to determine whether BMPR2 mutant
PMVECs have an absolute requirement for glutamine or
whether this represented an ‘‘arrangement of convenience’’
as a result of the presence of excess glutamine. We cultured
WT and BMPR2 mutant PMVECs in two concentrations of
glutamine, 500 mM (mimicking serum concentrations in
BMPR2 mutant patients) and 200 mM (representing the
lowest levels that would be considered normal in humans).
At 500 mM glutamine, BMPR2 mutant PMVECs show a net
proliferation that exceeds the rate of WT PMVECs at all
timepoints out to 72 h (Fig. 3a). At 200 mM glutamine, the
net proliferative rate of WT PMVECs is essentially
unchanged, but the BMPR2 mutant PMVECs are comple-
tely intolerant of glutamine-limited conditions and have all
died by 72 h (Fig. 3b).
To better understand the details of glutamine utilization
and the effects of glutamine limitation in BMPR2 mutant
PMVECs, we quantified total intracellular redox status of
WT and BMPR2 mutant PMVECs using two-photon auto-
fluorescence of endogenous NADH and FAD, the major
Fig. 1 Humans with PAH and impaired BMPR2 signaling exhibit sys-
temic and pulmonary vascular reprogramming of glutamine metabo-
lism. (a) Humans with BMPR2 mutations, irrespective of the presence
or absence of diagnosed PAH, have a statistically significant increase in
circulating glutamine compared to family members with WT BMPR2.
n¼ 11–24, *P< 0.02. (b) Transpulmonary glutamine uptake measured
at right heart catheterization is significantly increased in patients with
WHO Group I PAH compared to individuals with normal hemody-
namics and to individuals with WHO Group III PAH. n¼ 6–11,
*P< 0.05.
Pulmonary Circulation Volume 7 Number 1 | 189
electron carriers controlled by TCA cycle activity.
Fluorescence from both species allows calculation of the
optical redox ratio, with a higher ratio indicating more
TCA cycle activity, a more reduced intracellular redox
environment, and increased overall metabolic activity.
Conversely, a reduction in the optical redox ratio indicates
an overall decrease in metabolic activity, particularly via the
TCA cycle.28–30 Two-photon autofluorescence has very high
time resolution, allowing for rapid changes in the metabolic
and redox status of the cell to be detected and quantified.
We quantified the optical redox ratio in WT and BMPR2
mutant PMVECs under basal conditions and with acute
withdrawal of glutamine and glucose. At baseline, BMPR2
mutant PMVECs have a lower optical redox ratio than WT
cells (Fig. 4a), indicating a relatively impaired ability to
maintain the intracellular redox environment and relatively
impaired overall metabolic activity. With acute limitation of
TCA cycle substrates, WT PMVECs are able to rapidly
adapt their metabolic behavior to maintain the optical
redox ratio (Fig. 4a), whereas BMPR2 mutant PMVECs
show a significant further reduction in the optical redox
ratio (Fig. 4a), suggesting a significant loss of acute meta-
bolic flexibility.
We next examined the consequences of TCA cycle gluta-
mine dependence on mitochondrial function in BMPR2
mutant PMVECs. Cultured WT and BMPR2 mutant
PMVECs were given either glucose or glutamine as the
sole energy substrate available. Mitochondrial oxygen con-
sumption was quantified using the Seahorse XFe96 analyzer
and specific components of cellular respiration (ATP-linked
respiration, proton leak, and coupling efficiency) were
calculated from the oxygen consumption profiles
Fig. 2 BMPR2 mutant PMVECs shuttle significantly more glutamine into the TCA cycle. (a) Specific extracellular glutamine uptake flux rates for
BMPR2 mutant PMVECs are double those measured for WT PMVECs. n¼ 4 independent experiments, *P< 0.005 by two-tailed t-test. (b)
Concept schematic for [U-13C5]-L-glutamine labeling to determine carbon flow into the TCA cycle. (c) Compared to WT, BMPR2 mutant
PMVECs approximately double the amount of glutamine-derived carbon that is incorporated into multiple TCA cycle intermediates (citrate,
malate, and glutamate, the immediate precursor for a-ketoglutarate) by 13C %atom enrichment quantified by mass spectrometry. n¼ 4, *P< 0.05
by two-way ANOVA with Tukey post-hoc test. (d) 13C5-L-glutamine labeling and quantification of TCA cycle intermediates by mass spectrometry
shows a marked shift in the intracellular fate of glutamine-derived carbon in BMPR2 mutant PMVECs compared to WT, exemplified by the
isotopomers of malate. In WT cells, the majority of TCA cycle carbon is unlabeled, represented by the M0 isotopomer, indicating use of an
unlabeled carbon source (primarily glucose). By contrast,> 60% of the TCA carbon in the BMPR2 mutant PMVECs shows incorporation of at
least two labeled carbons, with 40% of the total malate pool being fully labeled, represented by the M4 isotopomer. n¼ 3 each for WT and
BMPR2 mutant.
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(see Supplemental Figure 1 for schematic). WT PMVECs
show equivalent ATP-linked respiration with glucose or glu-
tamine as the sole carbon source, but BMPR2 mutant
PMVECs show enhanced ATP-linked respiration with glu-
tamine as their carbon source compared to glucose (Fig. 4b).
When using glutamine, WT PMVECs exhibit increased
proton leak in the mitochondria compared to when using
glucose, but BMPR2 mutant cells maintain low levels of
proton leak with either glutamine or glucose (Fig. 4c), sug-
gesting that the overall efficiency for use of glutamine as a
fuel to support ATP synthesis is much greater in BMPR2
mutant PMVECs compared to WT. Consistent with this,
when comparing ATP-linked respiration to basal respira-
tion, WT endothelial cells exhibited a lower coupling effi-
ciency when using glutamine as fuel, whereas BMPR2
mutant PMVECs maintain a high coupling efficiency
(Fig. 4d). Taken together, these data indicated that gluta-
mine is the preferred substrate for energy production in
BMPR2 mutant PMVECs.
Oxidative stress drives HIF activation and SIRT3
impairment in BMPR2 mutants
We next wished to determine the molecular events down-
stream from BMPR2 mutation that contribute to glutamine
reliance. Multiple signaling pathways have been shown to
regulate increased glutamine utilization in a variety of dis-
ease contexts.15,31–35 Of the possible candidate pathways,
the pathway with the greatest relevance to PAH that
also potently regulates glutamine metabolism is hypoxia-
inducible factor 1-alpha (HIF1a). HIF1a has been shown
to be stabilized under normoxic conditions in experimental
and human PAH, and activation of HIF1a can induce
glutamine reliance.36–39 We found that BMPR2 mutant
PMVECs grown in culture exhibited significant normoxic
stabilization of HIF1a at the protein level compared to
WT (Fig. 5a and 5b), and that this was demonstrable for
two different PAH-associated BMPR2 mutation types. We
then treated WT and BMPR2 mutant PMVECs with cheto-
min, a pharmacologic inhibitor of HIF, and assessed glucose
and glutamine uptake by quantifying the extracellular flux
ratio of glutamine to glucose. Treatment of WT cells had no
effect on the glutamine to glucose flux ratio (Fig. 5c).
However, treating BMPR2 mutant PMVECs with the HIF
inhibitor significantly reduced the glutamine to glucose flux
ratio (Fig. 5c), suggesting that HIF1a activity helps to drive
the glutamine requirement in BMPR2 mutant endothelium.
Though HIF1a activation contributes to glutamine
uptake and utilization in BMPR2 mutant cells, we suspected
that there were additional alterations in signaling pathways
known to control metabolism. Activation of HIF1a by itself
has been shown to drive glutamine metabolism, but the
glutamine is disproportionately used for biosynthesis.39–41
Given the finding that glutamine in BMPR2 mutant
PMVECs is being used for energy production and not
obviously for disproportionate biosynthesis, we hypothe-
sized that a metabolic control pathway directly involved in
both glutamine regulation and energy production was likely
altered. Sirtuin-3 (SIRT3), a lysine deacetylase involved in
mitochondrial energy production and redox homeostasis,
emerged as a strong candidate. Loss of SIRT3 has been
shown to lie upstream of HIF1 activation and has been
associated with PH.15,42–44
Because sirtuin expression and activity is tightly regulated
by substrate availability, nutrient intake, physical activity,
and interacting signaling pathways operating between organ
systems, the role of SIRT3 in BMPR2-mediated PAH is best
studied in a murine model system. To investigate the role of
Fig. 3 BMPR2 mutant PMVECs require increased glutamine availability to manifest hyperproliferative behavior typical of PAH. (a) In glutamine-
limited conditions (0.2mM), WT PMVECs are able to maintain steady proliferation, but BMPR2R899X PMVEC begin to die rapidly after 24 h in
culture. (b) In more glutamine-replete conditions (0.5mM), WT PMVECs are essentially unaffected, whereas BMPR2R899X PMVECs exhibit the
hyperproliferative phenotype characteristic of PAH. n¼ 6 for each timepoint, *P< 0.01, **P< 0.001 by two-sided t-test.
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SIRT3 inactivation in BMPR2-mediated PAH, we isolated
mitochondria from WT and BMPR2 mutant
(BMPR2R899X) mice fed a Western diet (60% calories
from fat) for 8 weeks. Quality of the mitochondria-enriched
fraction was confirmed (Supplemental Figure 2) by demon-
strating the presence of COX4 and the absence of histone
H3 (nuclear protein) and a-tubulin (cytosolic protein),
and the mitochondrial proteome was assessed for acetyla-
tion of lysine residues, with SIRT3 inactivation leading to
lysine hyperacetylation. Compared to WT, BMPR2R899X
mitochondria had equivalent protein levels of SIRT3 but
exhibited significant lysine hyperacetylation of multiple
mitochondrial proteins (Fig. 6a, lanes 1–2 for WT and 5–6
for mutants, quantified in Fig. 6d), consistent with loss of
SIRT3 activity in BMPR2R899X mice.
Hyperacetylation of the mitochondrial proteome with no
change in SIRT3 protein content is consistent with loss of
SIRT3 enzymatic activity. We have previously shown that
the mitochondrial membranes specifically in BMPR2R899X
mice exhibit extensive lipid peroxidation as a function of
expression of the mutant BMPR2 isoform, and that the
lipid peroxidation is characterized by excess production of
covalent adducts between proteins and isoketals, a subset of
highly reactive lipid peroxidation products, specifically in
the lung around the microvessels.24,45 We and others have
also shown that lipid peroxidation products are increased in
humans with PAH.46–49 We thus hypothesized that SIRT3
was undergoing oxidative inactivation in the mitochondria
of BMPR2R899X mice, and that treatment with the isoketal
scavenger 2HOBA would restore normal SIRT3 activity
(schematic in Fig. 6b). We demonstrated the biochemical
plausibility of this hypothesis by incubating synthetically
pure isoketal with recombinant human SIRT3 in vitro.
Isoketal treatment inactivated SIRT3 in a concentration-
dependent manner as measured by luminescence via the
Sirt-Glo assay (Fig. 6c). We then directly tested the
Fig. 4 PAH-causing BMPR2 mutations drive mitochondrial dysfunction and metabolic reprogramming toward glutamine preference. (a)
Quantifying intracellular NADH and FADþ pools in live cells using two-photon autofluorescence to calculate the optical redox ratio showed WT
cultured human PMVECs retain metabolic flexibility by maintaining intracellular redox status despite limitation of the availability of glucose and
glutamine as carbon sources. By contrast, PMVECs expressing mutant BMPR2 exhibit substantial reduction of redox ratio when glucose and
glutamine are limited. n¼ 3 in standard media, n¼ 6 in glucose-free/glutamine-free media, *P< 0.05 by two-way ANOVA with Tukey post-hoc
testing. (b–d) Compared to WT, cultured murine PMVECs expressing mutant Bmpr2 exhibit enhanced glutamine-supported ATP-linked mito-
chondrial respiration ((b) **P< 0.0001 by ANOVA vs. all other groups), decreased leak respiration ((c) **P< 0.0001 by ANOVA vs. all other
groups), and increased coupling efficiency ((d), **P< 0.0001 by ANOVA vs. all other groups). n¼ 8–10 measurements for each condition per
experiment, experiments performed in duplicate.
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hypothesis that scavenging isoketals would preserve SIRT3
function by treating WT and BMPR2R899X mice with 1 g/L
2HOBA in their drinking water. Treatment with 2HOBA
significantly reduced lysine acetylation in the mitochondrial
proteome in BMPR2R899X mice compared to WT without
affecting total SIRT3 content in the mitochondria (Fig. 6a,
lanes 3–4 for WT and 7–8 for mutants, quantified in
Fig. 6d), consistent with preservation of SIRT3 catalytic
activity.
2HOBA normalizes glutamine metabolism
and prevents PAH in vivo
Having shown that impaired BMPR2 function is associated
with loss of SIRT3 function, and that this can be prevented
with 2HOBA treatment to scavenge damaging lipid perox-
idation products, we next wished to assess the in vivo meta-
bolic dysfunction downstream from BMPR2 mutation, the
relationship to PAH, and the effect of 2HOBA treatment.
We hypothesized that 2HOBA would prevent the develop-
ment of PAH in BMPR2R899X mice and would have a ben-
eficial modulatory effect on glutamine metabolism in vivo.
Expression of the BMPR2R899X allele was sufficient to drive
upregulation of glutamine synthetase in skeletal muscle
(Supplemental Figure 3) and in liver mitochondria (Fig. 7a)
compared to WT. Despite upregulation of glutamine synthe-
tase, circulating glutamine concentrations were equivalent in
vehicle-treated WT and BMPR2R899X mice (Fig. 7b), suggest-
ing that increased glutamine synthesis was being matched by
increased consumption in the BMPR2 mutants. Following
2HOBA treatment, BMPR2R899X mice had reduced gluta-
mine synthetase in liver mitochondria (Fig. 7a) and signifi-
cantly lower circulating glutamine compared to treated WT
mice (Fig. 7b), suggesting a favorable effect on glutamine
balance in the mutants. Consistent with the effects on
SIRT3 and glutamine metabolism, 2HOBA treatment pre-
vented the development of PH as measured by total
pulmonary resistance in the BMPR2R899X mice compared
to vehicle-treated mice (Fig. 7c). Treatment with 2HOBA
in the BMPR2R899X mice modestly increased cardiac
output (Supplemental Figure 4a) and decreased RVSP
(Supplemental Figure 4b), the combined effect of which
was to significantly reduce total pulmonary resistance.
Discussion
In these studies, we have used human and murine cell cul-
ture models, transgenic mice, and samples from living PAH
Fig. 5 Normoxic HIF1a activation in BMPR2 mutant PMVEC contributes to metabolic reprogramming. (a, b) HIF1a is increased under normoxic
conditions in two different types of BMPR2 mutations expressed in PMVEC (a) and is quantified by densitometry (b), n¼ 3 independent
experiments each for human and murine PMVECs, data analyzed in aggregate with *P< 0.05 by two-tailed t-test. (c) Treatment of BMPR2 mutant
PMVECs with low-dose chetomin, a pharmacologic inhibitor of HIF1a, significantly reduced the glutamine to glucose flux ratio while leaving WT
PMVEC essentially unaffected. n¼ 3 for each condition, *P< 0.05.
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patients to demonstrate a markedly altered metabolic pro-
gram for glutamine due to dysfunctional BMPR2 signaling
(Fig. 8). Loss of normal BMPR2 function leads to oxidant
injury in the mitochondria and formation of reactive pro-
ducts of lipid peroxidation termed isoketals.45 Isoketals
inactivate SIRT3 which, together with increased oxidant
stress, results in stabilization of HIF1a. Together, SIRT3
and HIF1a are two of the best established ‘‘master regula-
tor’’ pathways for cellular metabolism generally and gluta-
mine metabolism specifically. We show that this process can
be interrupted in vivo by treating with an orally bioavailable
scavenger of isoketals—2HOBA—and that interruption of
the molecular cascade leading to glutamine addiction pre-
vents the development of PAH.
Our findings add to the rapidly growing weight of evi-
dence implicating altered cellular metabolism as a major
contributor to the development and maintenance of PH.
The first major metabolic perturbation described in
PAH was a shift to lactate-producing glycolysis despite the
presence of ample oxygen concentrations to permit complete
glucose oxidation. This finding has now been replicated
in virtually every setting of experimental and human
PAH, and the molecular underpinnings continue to be clar-
ified.1,2,6,11,38,50–52 However, as has also been true for cancer
research, we and others are finding that the changes to the
cellular metabolic landscape in PAH are not restricted to
glycolysis, but rather appear to involve most of the major
metabolic pathways. Given the interconnectedness of the
Fig. 6 SIRT3 is inactivated in BMPR2R899X mice. (a) Mitochondria isolated from BMPR2R899X mice have equivalent SIRT3 content compared
to WT, but exhibit hyperacetylation of multiple mitochondrial proteins (lanes 1–2 and 5–6), indicating loss of SIRT3 function. Treatment of
BMPR2R899X mice with 2HOBA, a scavenger of isoketals, normalized mitochondrial protein acetylation state (lanes 3–4 and 7–8). Western images
are separate serial exposures of the same blot following stripping and reprobing with antibodies to the indicated proteins. (b) Schematic showing
how oxidative injury to the mitochondrial membrane is thought to inactivate SIRT3 via adduction by isoketals. (c) Purified recombinant human
SIRT3 activity measured by luminescence assay (Sirt-Glo, Promega) is dose-dependently inhibited by isoketals. (d) Densitometry quantification of
4–9 animals from experiments performed in triplicate. **P< 0.01 vs. all other groups by ANOVA with Tukey post-hoc testing.
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metabolome in healthy cells, this is perhaps not surprising.
Indeed, we have previously shown that expression of mutant
isoforms of BMPR2 in PMVECs is sufficient to reprogram
multiple metabolic pathways.51
Our findings help bring together several other recently
published reports concerning the altered metabolic program
in PH. Piao et al. showed increased right ventricular (RV)
glutaminolysis in monocrotaline-treated rats, and that a sig-
nature of increased glutaminolysis was also present in
the RV from human PAH patients.14 Paulin et al. recently
published that loss of SIRT3 activity through reduction at
the protein level predisposed mice to the development of
PAH, though the mechanism of downregulation was not
entirely clear.44 Extending these findings, Lai et al. have
very recently shown an important role for SIRT3 in PH
and the associated systemic metabolic derangements seen
in left heart failure with preserved ejection fraction.53
Diebold et al. reported metabolic remodeling in pulmonary
endothelial cells with reduced BMPR2 expression, though
manifestation of the PAH phenotype required exposure to
hypoxia, implicating HIF but not SIRT3.50,54 Our findings
fill in important gaps within and between these studies by
providing a possible mechanism by which all of these pub-
lished findings could be consistent with one another.
In addition, we provide evidence in living PAH patients
that dynamic metabolism is in fact reprogrammed in a
manner similar to what has been observed in model systems
and postmortem tissue. We have also shown that targeting
at least one of the mechanisms underlying metabolic repro-
gramming in PAH has beneficial effects in vivo, and we have
done so with a compound that can be used in humans.
2HOBA has a very favorable long-term safety profile,
with over 12 months of continuous dosing in mice produ-
cing no significant toxicity. 2HOBA is a naturally occurring
product, allowing expedited proof-of-principle studies
in humans, with subsequent studies focusing on related com-
pounds with improved pharmacokinetics. Importantly,
2HOBA’s mechanism of action has been demonstrated in
other disease models and across species.19,55
Our study does have some important limitations. We have
hypothesized a mechanism in which extensive mitochondrial
lipid peroxidation results in SIRT3 inactivation followed by
HIF1 stabilization. While there are published data placing
SIRT3 upstream of HIF1, there is also an extensive literature
on oxidative stress by itself being sufficient to activate HIF.
Our data could be consistent with concurrent inactivation of
SIRT3 and stabilization of HIF, both being driven by oxi-
dant injury. We were only able to quantify transpulmonary
metabolite gradients in a small number of patients and these
findings need expansion and independent replication. Our
studies have focused on glutamine as a carbon source,
which was necessary for acquiring a deeper understanding
of how glutamine trafficking in the pulmonary endothelium
becomes dysregulated in PAH. Indeed, even the findings
regarding glutamine as a carbon source as we have presented
them are likely only part of the story. Our own 13C labeling
Fig. 7 2HOBA lowers circulating glutamine and prevents the development of PAH in BMPR2R899X mice. (a) Glutamine synthetase in the liver
mitochondrial fraction is elevated in BMPR2R899X mice (lanes 5–6) compared to WT (lanes 1–2). 2HOBA treatment reduced glutamine
synthetase in the BMPR2R899X mice (lanes 7–8) but not substantially in WT (lanes 3–4). Western images are separate serial exposures of the same
blot following stripping and reprobing with antibodies to the indicated proteins. (b) Treatment with 2HOBA significantly reduces plasma glutamine
availability in BMPR2R899X mice compared to 2HOBA-treated WT mice. n¼ 6–29, *P< 0.05. (c) 2HOBA treatment reduced total pulmonary
resistance in BMPR2R899X mice to a level statistically indistinguishable from WT. n¼ 5–14, *P< 0.02 by ANOVA with Tukey post-hoc analysis.
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data indicate that complex carbon cycling through the pyr-
uvate pool is occurring, as shown by the presence of the M3
isotopomer in the BMPR2 mutant PMVECs (Fig. 2d) and
the presence of excess label incorporation in the alanine pool
but not in the lactate pool (Supplemental Figure 5). This may
be related to a degree of carbon flux through the pyruvate
carboxylate pathway, as has been found in another recent
study examining upregulation of vascular glutaminolysis in
PAH.56 A deeper understanding of the utilization and traf-
ficking of glutamine as a carbon source in PAH will be a goal
of our ongoing studies, not only to address these questions,
but also to address issues such as how changes in TCA inter-
mediates such as succinate or 2-oxoglutarate (neither of
which were quantified in the present study, but which very
likely are impacted by changes in glutaminemetabolism)may
impact directly on HIF activation.57,58 Besides engaging in
complex biochemistry as a carbon source, glutamine can also
serve as an important nitrogen source, contributing to
biosynthetic pathways for nucleic acids and amino acids as
well as participation in the urea cycle and nitrogen cycling
pathways. Our studies were not structured to capture this
aspect of glutamine metabolism and this will likely be a fruit-
ful avenue of inquiry in future studies. Our work deliberately
did not address the use and fate of fat-derived carbon in
BMPR2 mutant endothelium. Fatty acid carbon trafficking
is much more important in normal endothelial biology than
was previously realized.59 While we have previously
addressed fatty acid metabolism in BMPR2 mutant tissues,
and we have previously shown evidence for downregulation
of key fat metabolism genes in BMPR2 mutant pulmonary
endothelial cells, the detailed complexities of utilization of
multiple carbon sources were beyond the scope of this
report.9,12,13,51
In summary, we have shown that metabolic reprogram-
ming in the pulmonary endothelium driving BMPR2-
mediated PAH involves glutamine addiction as an
Fig. 8 Schematic of BMPR2-mediated metabolic reprogramming. The normal pulmonary endothelium relies mainly on glucose as its bioenergetic
fuel. When normal BMPR2 signaling is lost, oxidant injury in the mitochondria drives inactivation of SIRT3 via adduction by isoketals. This can be
interrupted with 2HOBA. Unchecked, however, continued oxidant injury and SIRT3 inactivation (either in sequence or in parallel) lead to HIF
stabilization, all of which drives a hyperproliferative, glutamine avid pulmonary endothelial phenotype that underlies the development of PAH.
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important molecular feature. Glutamine becomes an indis-
pensable, preferred carbon source in the BMPR2 mutant
pulmonary endothelium, permitting hyperproliferation
characteristic of PAH. Glutamine addiction appears to be
driven downstream from BMPR2 by decreases in SIRT3
activity and increased HIF1a signaling. Interruption of
this pathway in BMPR2 mutant mice with a molecularly
targeted therapy that is directly translatable to humans in
large part ameliorates disease. The finding that glutamine
avidity is present in humans with WHO Group I PAH sug-
gests that 2HOBA and other therapies targeting metabolic
reprogramming have a high likelihood of benefit in PAH
and delays to trials of these interventions in PAH patients
should be minimized.
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